Karat Packaging Q3 net income drops 38% to $4.73 million; Q3 net sales rise 8% to $134.74 million
Bitget2026/11/05 22:08- Karat Packaging’s third-quarter 2026 diluted earnings fell 39% year over year to $0.22 per share.
- Net sales rose 8% to $134.7 million, primarily driven by volume growth and product mix.
- Higher import and domestic shipping costs, along with elevated resin prices, pressured margins and contributed to results below management’s expectations.
- Four additional chain accounts secured during the quarter are expected to begin receiving shipments in the first half of 2027.
- Fourth-quarter 2026 guidance calls for net sales growth of 9%–11% year over year and gross margin of 33%–35%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Crypto prices
More
